5.2 Tirzepatide (SURMOUNT Trials) Tirzepatide demonstrated even greater mean weight loss in SURMOUNT trials. Findings included: Weight reductions exceeding 20% in some cohorts Dose-dependent gastrointestinal symptoms Lean mass reduction proportional to total weight loss Again, detailed micronutrient panels were not central trial endpoints
This is directly relevant for anyone on GLP 1 medications
Some data suggests that injecting before 8am may produce slightly lower post-prandial glucose levels compared to evening injections, with one analysis showing a 15% improvement in post-meal blood sugar management
This, in turn, means doctors will be able to make more informed choices about the best medication to prescribe to patients, Reitano said "If that list is outdated to reality, then you're going to write a prescription assuming that the patient is able to get access to it," Reitano said
However, in highly invasive breast cancer cell lines MDA-MB-231 and MDA-MB-468, high concentrations (100 nM) of liraglutide promote breast cancer progression by activating GLP-1R via the NOX4/ROS/VEGF signaling pathway [18]